Assessing the Burden of Hyperkalemia

Slides:



Advertisements
Similar presentations
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
Advertisements

Overview The Burden of COPD Main Challenges in the Diagnosis of COPD.
Prior Trials of RAAS Inhibitors
Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.
Emerging Concepts in Heart Failure
EMPHASIS-HF Extended Follow-up
Current State of Hyperkalemia Management
Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.
Chronic Hepatitis C Virus Infection
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
Starting Strong: Initial Evaluation of the Patient With HCV
PCP Perspectives Pathophysiologic Principles in the Management of Hyperkalemia.
A Paradigm Shift in PAH.
HCV: Who Should We Screen and Why?
Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.
Heart Rate, HF Admissions, and Readmissions
New Therapies for Hyperkalemia Across the Continuum of Care
A CASE CHALLENGE IN HFrEF:
UNDERSTANDING RISK STRATIFICATION IN PAH:
Emerging Data on ACS Management From ACC
At The Cutting Edge of Developments in the Management of Hyperkalemia
Updates Abound in Hyperkalemia Management
A New Era for NOACs:.
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.
Updates on Outcomes for Novel T2D Therapies
PCP Perspectives Clinical Considerations in Hyperkalemia
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
SGLT2 Inhibitors in the Modern Era: Why and Where?
Beyond Statin Therapy.
The Vicious Cycle of Chronic Migraine How Can the Physician Help?
Tailoring Hemophilia Prophylaxis Therapy
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Treating HFrEF: Challenges Faced
Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.
Expert Perspectives on Hyperkalemia for the Specialist
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
Exploring Emerging Treatments for Hyperkalemia
PCSK9 Inhibitors and Cardiovascular Outcomes
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
At The Cutting Edge of Developments in the Management of Hyperkalemia
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Multidisciplinary Management of Hyperkalemia:
Hyperkalemia in the Hospital
Management of Systematic Lupus Erythematosus
Shifting Currents in Hyperkalemia Management 2015 in Review
Shifting Currents in Hyperkalemia Management 2015 in Review
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.
CAD and HF Often Coexist
A Guideline-Based Approach to HCV Care
Are We Making Progress in the Management of Huntington Disease?
Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.
Improving Adherence to Antiplatelet Therapy After an ACS Event
Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators
Breaking Down the Data in Hyperkalemia
Assessing the Burden of Hyperkalemia
PCSK9 Inhibitors and Statin Intolerance
Championing Evidence-Based Care in Patients With Acute Low Back Pain
Uptitration of Medications in HF: Start Low but Aim High and Stay High
Minimal Residual Disease and Hematologic Malignancies
Challenges and Emerging Solutions in Anemia Management Explored
Clinical Comparisons.
Improving Management of Acute HTN in Patients With Stroke
Top Tips in Evidence-Based Care for HFrEF
Key Data on Improving Outcomes in HF Patients
RAASi Enabling in the Modern Era
PCSK9 Inhibitors and Real-World Evidence
Case-Based Look at Hyperkalemia Identification, Diagnosis, and Management.
Potassium Situations Resolved
Presentation transcript:

Assessing the Burden of Hyperkalemia

Program Goals

Program Overview

Hyperkalemia Definition, Prevalence, and Clinical Effects

Causes of Hyperkalemia

Patients at Risk of Hyperkalemia

Burden of Hyperkalemia

Increasing Incidence of Hyperkalemia

Hyperkalemia-Associated ED Visits

PARADIGM-HF

PARADIGM-HF Hyperkalemia Development During Study

Acute Treatment of Hyperkalemia

Guidelines Recommendations Regarding RAAS Inhibitor Use Based on Serum K+ Level

Chronic Management of Hyperkalemia Before Era of New K+ Binders

SPS

New K+ Binder Patiromer

Emerging K+ Binder ZS-9

New and Emerging K+ Binders Efficacy and Safety

ZS-9 Treatment Effect in Patients With HF Receiving Maximal, Submaximal, or No RAAS Inhibitor Therapy

Long-Term Efficacy and Safety of Patiromer

Long-Term Efficacy and Safety of ZS-9

Potential Benefits of New and Emerging K+ Binders

Management of Hyperkalemia From Acute to Chronic Care

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.